[go: up one dir, main page]

SE9603725D0 - New teatment - Google Patents

New teatment

Info

Publication number
SE9603725D0
SE9603725D0 SE9603725A SE9603725A SE9603725D0 SE 9603725 D0 SE9603725 D0 SE 9603725D0 SE 9603725 A SE9603725 A SE 9603725A SE 9603725 A SE9603725 A SE 9603725A SE 9603725 D0 SE9603725 D0 SE 9603725D0
Authority
SE
Sweden
Prior art keywords
treatment
teatment
new
polyposis
widal
Prior art date
Application number
SE9603725A
Other languages
English (en)
Swedish (sv)
Inventor
Per Linberg
Masso Jan Pinas
Jordi Serra-Carreras
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9603725A priority Critical patent/SE9603725D0/xx
Publication of SE9603725D0 publication Critical patent/SE9603725D0/xx
Priority to UA99042004A priority patent/UA59374C2/uk
Priority to IDW990139D priority patent/ID23692A/id
Priority to CZ0122999A priority patent/CZ298799B6/cs
Priority to SI9730492T priority patent/SI0946175T1/xx
Priority to PCT/SE1997/001651 priority patent/WO1998016228A1/en
Priority to AT97945135T priority patent/ATE230597T1/de
Priority to BR9711896A priority patent/BR9711896A/pt
Priority to TR1999/00770T priority patent/TR199900770T2/xx
Priority to PL332692A priority patent/PL190902B1/pl
Priority to CNB971985847A priority patent/CN1146416C/zh
Priority to IL12932497A priority patent/IL129324A0/xx
Priority to RU99109596/14A priority patent/RU2197966C2/ru
Priority to CA002268305A priority patent/CA2268305C/en
Priority to ES97945135T priority patent/ES2188995T3/es
Priority to DE69718347T priority patent/DE69718347T2/de
Priority to DK97945135T priority patent/DK0946175T3/da
Priority to EP97945135A priority patent/EP0946175B1/en
Priority to JP51824698A priority patent/JP4100713B2/ja
Priority to KR10-1999-7003115A priority patent/KR100510812B1/ko
Priority to AU46409/97A priority patent/AU738310B2/en
Priority to YUP-163/99A priority patent/RS49599B/sr
Priority to EEP199900118A priority patent/EE04043B1/xx
Priority to SK384-99A priority patent/SK284252B6/sk
Priority to HU0000036A priority patent/HUP0000036A3/hu
Priority to NZ334786A priority patent/NZ334786A/xx
Priority to PT97945135T priority patent/PT946175E/pt
Priority to ZA9708842A priority patent/ZA978842B/xx
Priority to TW086114622A priority patent/TW568784B/zh
Priority to MYPI97004697A priority patent/MY117918A/en
Priority to ARP970104655A priority patent/AR008886A1/es
Priority to SA97180641A priority patent/SA97180641B1/ar
Priority to NO19991619A priority patent/NO321007B1/no
Priority to IS5021A priority patent/IS1930B/is
Priority to HK00102015A priority patent/HK1022848A1/xx
Priority to US09/833,599 priority patent/US6599927B2/en
Priority to US09/833,699 priority patent/US6380222B2/en
Priority to US10/459,299 priority patent/US20030216439A1/en
Priority to US11/058,090 priority patent/US20060025450A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
SE9603725A 1996-10-11 1996-10-11 New teatment SE9603725D0 (sv)

Priority Applications (39)

Application Number Priority Date Filing Date Title
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment
UA99042004A UA59374C2 (uk) 1996-10-11 1997-01-10 Лікування назальних поліпів (варіанти) за допомогою інгібітора н+, к+ -атфази, фармацевтична композиція на його основі
PT97945135T PT946175E (pt) 1996-10-11 1997-10-01 Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
JP51824698A JP4100713B2 (ja) 1996-10-11 1997-10-01 鼻ポリープの治療におけるｈ▲上＋▼，ｋ▲上＋▼―ａｔｐアーゼ阻害剤の使用
AU46409/97A AU738310B2 (en) 1996-10-11 1997-10-01 Use of an H+, K+-ATPase inhibitor in the treatment of nasal polyps
SI9730492T SI0946175T1 (en) 1996-10-11 1997-10-01 USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS
PCT/SE1997/001651 WO1998016228A1 (en) 1996-10-11 1997-10-01 USE OF AN H+, K+-ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS
AT97945135T ATE230597T1 (de) 1996-10-11 1997-10-01 Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen
EEP199900118A EE04043B1 (et) 1996-10-11 1997-10-01 H+,K+-ATPaasi inhibiitori ja glükokortikoidide kasutamine ravimvormi valmistamiseks
TR1999/00770T TR199900770T2 (xx) 1996-10-11 1997-10-01 Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
PL332692A PL190902B1 (pl) 1996-10-11 1997-10-01 Zastosowanie inhibitora H໋ , K໋ -ATPazy i glukokortykoidu oraz preparat farmaceutyczny
CNB971985847A CN1146416C (zh) 1996-10-11 1997-10-01 H+、k+-腺苷三磷酸酶抑制剂在制备治疗鼻息肉药物中的用途
IL12932497A IL129324A0 (en) 1996-10-11 1997-10-01 Use of an H<+>, K<+>-ATPase inhibitor in the treatment of nasal polyps
RU99109596/14A RU2197966C2 (ru) 1996-10-11 1997-10-01 Применение ингибитора н+, к+-атфазы для лечения носовых полипов
CA002268305A CA2268305C (en) 1996-10-11 1997-10-01 Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
ES97945135T ES2188995T3 (es) 1996-10-11 1997-10-01 Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
DE69718347T DE69718347T2 (de) 1996-10-11 1997-10-01 VERWENDUNG EINER ZUSAMMENSETZUNG AUS H+, K+ -ATPase-INHIBITOREN UND GLUCOCORTIKOIDEN ZUR BEHANDLUNG VON NASENPOLYPEN
DK97945135T DK0946175T3 (da) 1996-10-11 1997-10-01 Anvendelse af en kombination af H+,K+ATPase inhibitorer og glucocorticoider til behandling af nasale polypper
EP97945135A EP0946175B1 (en) 1996-10-11 1997-10-01 USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS
IDW990139D ID23692A (id) 1996-10-11 1997-10-01 Penggunaan sebuah penghambat h<+>, k<+>-atpase pada perawatan polip-polip nasal
KR10-1999-7003115A KR100510812B1 (ko) 1996-10-11 1997-10-01 비용종 치료에서 Ｈ+, Ｋ+-ＡＴＰａｓｅ 저해제의 용도
YUP-163/99A RS49599B (sr) 1996-10-11 1997-10-01 Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
CZ0122999A CZ298799B6 (cs) 1996-10-11 1997-10-01 Použití inhibitoru H+, K+ - ATPázy pro lécbu nazálních polypu
BR9711896A BR9711896A (pt) 1996-10-11 1997-10-01 Uso de um inibidor h+,k+atpase e um glicocorticÄide processos para o tratamento de um pÄlipo nasal da sindrome de widal e de asma e formula-{es farmac-uticas para uso sumult-neo separado ou sequencial no tratamento da s¡ndrome de widal e para administra-Æo simult-nea separada ou sequencial no tratamento da asma
SK384-99A SK284252B6 (sk) 1996-10-11 1997-10-01 Použitie inhibítora H+, K+ -ATPáz a glukokortikoidu v terapii a farmaceutická kompozícia s ich obsahom
HU0000036A HUP0000036A3 (en) 1996-10-11 1997-10-01 Use of an h+,k+-atpase inhibitor in the treatment of nasal polyps
NZ334786A NZ334786A (en) 1996-10-11 1997-10-01 Use of a Hydrogen, Potassium-ATPase inhibitor in the treatment of nasal polyps, asthma and Widal's syndrome
ZA9708842A ZA978842B (en) 1996-10-11 1997-10-02 Use of an H<+>, K<+>-ATPase inhibitor in the treatment of nasal polyps.
TW086114622A TW568784B (en) 1996-10-11 1997-10-07 Pharmaceutical composition for treating nasal polyps and Widal's syndrome comprising H+, K+-ATPase inhibitor
MYPI97004697A MY117918A (en) 1996-10-11 1997-10-07 Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
ARP970104655A AR008886A1 (es) 1996-10-11 1997-10-08 Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
SA97180641A SA97180641B1 (ar) 1996-10-11 1997-11-23 استخدام توليفة من مثبطات إنزيم k+ atpase h + glucocorticoids nasal polyps وجوكوكورتيكويدات في علاج السليلات الأنفية
NO19991619A NO321007B1 (no) 1996-10-11 1999-04-06 Anvendelse av en H+,KC-ATPase-inhibitor og et glukokortikoid ved behandlingen av Widals syndrom og nesepolypper, samt en farmasoytisk formulering som innbefatter en H+,K+-ATPase-inhibitor og et glukokortikoid
IS5021A IS1930B (is) 1996-10-11 1999-04-08 Notkun samsetningar H+, K+ -ATPasa tálma og sykurstera í meðhöndlun á nefsepagerum
HK00102015A HK1022848A1 (en) 1996-10-11 2000-04-03 Use of a combination of h+, k+-atpase inhibitors and glucocorticoids in the treatment of nasal polyps
US09/833,599 US6599927B2 (en) 1996-10-11 2001-04-13 Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
US09/833,699 US6380222B2 (en) 1996-10-11 2001-04-13 Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
US10/459,299 US20030216439A1 (en) 1996-10-11 2003-06-11 Use of an H+, K+-ATPase inhibitor in the treatment of asthma
US11/058,090 US20060025450A1 (en) 1996-10-11 2005-02-14 Use of an H+, K+ -ATPase inhibitor in the treatment of asthma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment

Publications (1)

Publication Number Publication Date
SE9603725D0 true SE9603725D0 (sv) 1996-10-11

Family

ID=20404214

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment

Country Status (34)

Country Link
EP (1) EP0946175B1 (es)
JP (1) JP4100713B2 (es)
KR (1) KR100510812B1 (es)
CN (1) CN1146416C (es)
AR (1) AR008886A1 (es)
AT (1) ATE230597T1 (es)
AU (1) AU738310B2 (es)
BR (1) BR9711896A (es)
CA (1) CA2268305C (es)
CZ (1) CZ298799B6 (es)
DE (1) DE69718347T2 (es)
DK (1) DK0946175T3 (es)
EE (1) EE04043B1 (es)
ES (1) ES2188995T3 (es)
HK (1) HK1022848A1 (es)
HU (1) HUP0000036A3 (es)
ID (1) ID23692A (es)
IL (1) IL129324A0 (es)
IS (1) IS1930B (es)
MY (1) MY117918A (es)
NO (1) NO321007B1 (es)
NZ (1) NZ334786A (es)
PL (1) PL190902B1 (es)
PT (1) PT946175E (es)
RS (1) RS49599B (es)
RU (1) RU2197966C2 (es)
SA (1) SA97180641B1 (es)
SE (1) SE9603725D0 (es)
SK (1) SK284252B6 (es)
TR (1) TR199900770T2 (es)
TW (1) TW568784B (es)
UA (1) UA59374C2 (es)
WO (1) WO1998016228A1 (es)
ZA (1) ZA978842B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE69939022D1 (de) 1998-08-18 2008-08-14 Univ California Epidermale wachstumsfaktor rezeptor antagonisten zur behandlung stark vermehrter schleimsekretion in der lunge
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
DK1555038T3 (da) * 1999-03-03 2011-10-17 Optinose As Nasal administrationsindretning
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
US20050131026A1 (en) * 2002-03-14 2005-06-16 Atlanta Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
AU2003227710A1 (en) * 2002-05-07 2003-11-11 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
RS95204A (en) * 2002-05-07 2006-12-15 Altana Pharma Ag. Combination for the treatment of airway disorders
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
PL375819A1 (en) 2002-12-12 2005-12-12 Altana Pharma Ag Combination medicament
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004271744B2 (en) 2003-09-16 2010-07-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델
JP7614938B2 (ja) 2021-05-11 2025-01-16 日立Astemo株式会社 サスペンション制御装置、およびサスペンション制御方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Also Published As

Publication number Publication date
PL332692A1 (en) 1999-09-27
EE04043B1 (et) 2003-06-16
DE69718347T2 (de) 2003-08-28
RU2197966C2 (ru) 2003-02-10
DE69718347D1 (de) 2003-02-13
CA2268305A1 (en) 1998-04-23
CN1146416C (zh) 2004-04-21
NO991619D0 (no) 1999-04-06
NZ334786A (en) 2000-12-22
IL129324A0 (en) 2000-02-17
JP4100713B2 (ja) 2008-06-11
AU4640997A (en) 1998-05-11
BR9711896A (pt) 1999-08-24
SK284252B6 (sk) 2004-12-01
IS5021A (is) 1999-04-08
ID23692A (id) 2000-05-11
RS49599B (sr) 2007-06-04
KR20000049046A (ko) 2000-07-25
MY117918A (en) 2004-08-30
EE9900118A (et) 1999-10-15
CZ298799B6 (cs) 2008-02-06
ATE230597T1 (de) 2003-01-15
NO991619L (no) 1999-04-06
CN1232397A (zh) 1999-10-20
HU0000036D0 (es) 2002-05-29
TR199900770T2 (xx) 1999-06-21
WO1998016228A1 (en) 1998-04-23
SA97180641B1 (ar) 2005-12-18
PL190902B1 (pl) 2006-02-28
DK0946175T3 (da) 2003-03-17
AR008886A1 (es) 2000-02-23
NO321007B1 (no) 2006-02-27
JP2001508034A (ja) 2001-06-19
EP0946175B1 (en) 2003-01-08
CZ122999A3 (cs) 1999-09-15
KR100510812B1 (ko) 2005-08-31
PT946175E (pt) 2003-04-30
YU16399A (sh) 2000-03-21
HUP0000036A2 (hu) 2002-05-29
CA2268305C (en) 2006-11-28
ZA978842B (en) 1998-04-14
HUP0000036A3 (en) 2003-02-28
HK1022848A1 (en) 2000-08-25
UA59374C2 (uk) 2003-09-15
AU738310B2 (en) 2001-09-13
EP0946175A1 (en) 1999-10-06
SK38499A3 (en) 2000-03-13
ES2188995T3 (es) 2003-07-01
IS1930B (is) 2004-05-18
TW568784B (en) 2004-01-01

Similar Documents

Publication Publication Date Title
SE9603725D0 (sv) New teatment
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
AU3984597A (en) Formulation of 5-ht agonists
WO2002041837A3 (en) Treatment of mucositis
EP1028715A4 (en) FORMULATION FOR NASAL SUPPORT AND METHOD OF USE THEREOF
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
MX9603596A (es) Perfluoropolieteres o composiciones de los mismos para prevencion y tratamiento de infecciones virales topicas.
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
DE69911401D1 (en) Immunoregulator
GB9521608D0 (en) Pharmaceutical composition
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
EP0744176A3 (en) Methods for inhibiting bone loss
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
PT980253E (pt) Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
WO2001016355A3 (de) In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk